

  • Categories
    • Travel
    • Food
    • Hotels
    • Tech
    • Cooking
  • Best Picks
  • Review
  • Blog
  • Video
  • Wiki
  • 


  •  Home
  •  Videos
  •  Posts
  •  Contact
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-05-22, 14:45

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Kaitlyn Granata

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-05-22, 04:00

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Britney MacDevitt

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-04-16, 18:00

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Micheal Moe

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-01, 14:05

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-09, 02:25

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-04-28, 20:23

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-02-19, 19:05

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Lesley Moroney

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-09-09, 22:45

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-08-27, 14:05

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

Britney MacDevitt

Popular Posts
  • Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now

    likes . 0 comments
  • Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

    likes . 0 comments
  • SHINEPR EARNS WOMEN’S BUSINESS ENTERPRISE CERTIFICATION

    likes . 0 comments
  • Istation names Rich Watson as Chief Revenue Officer

    likes . 0 comments
  • Industry leaders to speak at Wood Mackenzie’s Carbon Capture, Utilization and Storage Conference 2024

    likes . 0 comments

Email: info@10toptenreviews.com

10 Top Ten Reviews is part of VSG Solution JSC, an international media group and leading digital publisher.

© 2021 - 10TopTenReiews All Rights Reserved.